NCT05596266View on ClinicalTrials.gov

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

October 25, 2025

Conditions
T-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD5 CAR-T

CD5 CAR-T will be administered by I.V. infusion.

Trial Locations (1)

Unknown

RECRUITING

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
collaborator

Baoding Children's Hospital

OTHER

lead

Xuanwu Hospital, Beijing

OTHER

NCT05596266 - CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter